Sylvester Comprehensive Cancer Center, part of UHealth–the University of Miami Health System, and Syapse, a precision oncology company, announced that they will team up to launch a new precision medicine initiative at Sylvester.
Invitae Corp. announced the launch of the Invitae Patient Insights Network, a permission-based, patient-centered network designed to make it easy for patients to share health experiences, contribute de-identified clinical data, and maintain their privacy while being connected to the latest research, treatment, and disease education opportunities.
The Leukemia & Lymphoma Society made a $4 million funding commitment in an investigational therapy being developed by Forty Seven Inc. for lymphoma patients.
The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) for an additional 13 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
Former Vice President Joe Biden said he plans to launch the Biden Cancer Initiative, which would focus on data sharing, quality of cancer care, patient access, and increasing participation in clinical trials.
Oncologists must confront end-of-life issues on a nearly daily basis. Our approach to the potential death of a patient may change over time, however, depending on the patients' diagnosis and stage, where those patients are in their treatment plan, and, of course, what the patients' wishes are. When feasible, our primary goal is to prevent death from cancer, and when we cannot achieve that, we try to delay death as long as we can. When dying seems inevitable, we do our best to make it as comfortable as possible.
A budget proposed by President Donald Trump would set NIH and biomedical research back 15 years, said former Vice President Joe Biden, addressing members of the American Association for Cancer Research on April 3.
FDA approved Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
FDA granted an accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
